BRAINAURORA-B (06681): Multi-domain digital therapeutic DELIGHT study published in eClinicalMedicine reveals new mechanism of "brain-heart co-treatment"

date
06:15 20/11/2026
avatar
GMT Eight
BRAINAURORA-B (06681) announced that the DELIGHT study (a multicenter, double-blind, randomized controlled trial, NCT05704270), jointly conducted by the Group, Professor Ma Changsheng's team at Beijing Anzhen Hospital Affiliated to Capital Medical University, and Professor Wang Jiguang's team at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, was officially published on November 18, 2026 in eClinicalMedicine (2025 Journal Impact Factor: 12.8, Q1), a sub-journal of The Lancet and a top international academic journal.
BRAINAURORA-B (06681) announced that the DELIGHT study (a multicenter, double-blind, randomized controlled trial, NCT05704270), jointly conducted by the Group with Professor Ma Changsheng's team at Beijing Anzhen Hospital Affiliated to Capital Medical University and Professor Wang Jiguang's team at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, was officially published on November 18, 2026 in eClinicalMedicine (2025 Journal Impact Factor: 12.8, Q1), a sub-journal of The Lancet and a top international academic journal. The study is the first to focus on the population with hypertension complicated by mild cognitive impairment (MCI), systematically evaluating the intervention effects of 12-week multi-domain adaptive computerized cognitive training (MD-CCT), and, combined with ultra-high-field 7T magnetic resonance imaging (MRI) technology, revealing the potential mechanism by which digital cognitive therapy works through the "brain-heart axis." Cognitive training not only improved patients' cognitive function but also significantly improved cardiovascular issues such as heart rate in hypertensive patientsthat is, "training the brain" effectively reduced cardiovascular load. This finding highlights the clinical value of "brain-heart integration, joint prevention and treatment," provides new and strong evidence-based support for non-pharmacological intervention in hypertension, and brings good news for the treatment of 270 million hypertensive patients. The study opens up a major future direction for the industry in the joint treatment of heart and brain, and also opens broader prospects for cognitive training in the cardiovascular disease field. Hypertension and cognitive impairment are the two most common health challenges among the elderly population. The number of hypertensive patients in China is as high as 270 million, and international literature shows that the incidence of cognitive impairment among hypertensive patients reaches 30-50%. Long-term hypertension can damage cerebral blood vessels and lead to cognitive decline; impaired cognitive function can also reduce patients' quality of life and adherence to antihypertensive treatment. Among the elderly population aged over 65, the prevalence of hypertension exceeds 75%, and hypertensive patients have an approximately 70% increased risk of developing moderate-to-late-stage dementia. Previous studies mostly focused on the one-way approach of "controlling blood pressure to protect the brain," while high-quality evidence has previously been lacking on whether cognitive intervention targeting the brain can in turn improve cardiovascular health. The DELIGHT study was jointly conducted by 11 hospitals in China and enrolled a total of 217 patients with hypertension complicated by MCI, who were randomly divided into two groups at a 1:1 ratio: Intervention group (n=108): received 12-week multi-domain adaptive CCT (MD-CCT) for comprehensive training across multiple cognitive function domains; after completing the initial 12 weeks of training, patients were randomized again to determine whether to continue training or stop training for the next 12 weeks, in order to observe the durability of effects. Positive control group (n=109): received CCT targeting only the two basic cognitive domains of perception and attention (FD-CCT). Patients in both groups used the Group's self-developed "Brain Function Information Management Platform Software System" (Class II medical device, Xiang Medical Device Registration Approval: 20182210142) for training. Standardized cognitive scale assessments and standardized blood pressure and pulse pressure measurements were performed at baseline, 12-week, and 24-week follow-up; multimodal MRI scans (including resting-state functional MRI and structural imaging) were performed on 32 of the patients before and after training, focusing on tracking changes in functional connectivity and gray matter density of the ventral attention network (VAN) and executive control network (ECN). Key findings: Improvement in brain microstructure: Functional connectivity of neural networks in patients' brains responsible for attention, executive control, and episodic memory was significantly enhanced; gray matter density in the hippocampus, the core hub of memory, increased significantly, suggesting that cognitive training not only activates brain function but also improves brain tissue structure to a certain extent. Cross-system benefits: Compared with the control group, patients receiving MD-CCT training not only showed improved cognitive function but also significantly optimized cardiovascular indicators, manifested as lower diastolic blood pressure and steadier heart rate, with a significant decrease in the rate-pressure product (RPP, a core indicator reflecting myocardial oxygen consumption and workload), suggesting that systematic cognitive intervention can "reduce the burden" on the heart. "Brain-heart axis" mechanism: Mediation effect analysis showed that improvement in functional connectivity of brain neural networks is the key bridge linking "cognition" and "heart"; improvement in functional connectivity was significantly negatively correlated with heart rate reductionthat is, the more efficient the brain network connectivity, the more obvious the heart rate reduction and the steadier the heartbeat. 24-week long-term follow-up: The 24-week follow-up showed that whether patients continued training in the latter 12 weeks (MD-keep group) or stopped training (MD-stop group), the reduction in diastolic blood pressure in both subgroups remained significantly better than that in the FD-CCT control group, suggesting that the protective effect of 12 weeks of high-quality cognitive training on the cardiovascular system is durable. This study provides a new perspective for the treatment of hypertension complicated by cognitive impairmentnamely, that "training the brain" effectively reduces cardiovascular load, bringing good news to hypertensive patients and also meaning that the Company's products have opened up broad new market space for long-term treatment of these patients. Based on the available evidence, multi-dimensional digital cognitive training is not only a rehabilitation method targeting the brain but also a new non-pharmacological intervention strategy that can simultaneously stimulate neuroplasticity and improve cardiovascular function. This intervention model can effectively complement traditional vascular risk management such as antihypertensive drugs; at the same time, digital therapy has high safety, no risk of drug interactions, and can break the physical and temporal constraints of traditional rehabilitation, enabling patients to receive standardized intervention in the community or at home and improving treatment accessibility. The Group's scientific research team, led by Chief Executive Officer Cai Longjun, deeply participated in this study. The Board believes that the above results reflect the Group's leading capabilities in cognitive digital therapy and real-world research and clinical translation in "brain-heart comorbidity," further expanding the Group's evidence-based evidence map for digital therapy, consistent with the Group's long-term development strategy, conducive to consolidating the Group's industry-leading position in the field of digital therapy for cognitive impairment, and creating long-term value for shareholders.